# Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

> **NCT06523699** · PHASE1 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Recombinant glycosylated human interleukin-7
- **DRUG:** Melphalan
- **PROCEDURE:** Autologous hematopoietic cell transplant

## Key facts

- **NCT ID:** NCT06523699
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-04
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06523699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06523699, "Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06523699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*